REGENESIS: REvolutionising bone and cartilaGE reconstruction through Novel cell-instructive biomaterial and peptide-Enhanced Stem cell Immobilization Strategy
| Project code: | PR-13605 Basic, Multilateral |
| Call: | M-era.net 2024 |
| Financed by: |
Ministry of Higher Education, Science and Innovation (MVZI)
|
| ID: | pride v juniju |
| Duration: |
2025 - 2028 |
| Principal Investigator: | Dr Małgorzata Gazińska (WUST, Poland), Dr Aleksandra Szwed-Georgiou (UL, Poland), Prof. Sylwia Rodziewicz- Motowidło (UG, Poland), Dr Marta Klak (Polbionica, Poland), Prof. Diego Mantovani (LU, Canada), Dr Eric Quenneville (Biomomentum, Canada) , Asst. Prof Marija Vukomanović (K9) |
Osteochondral defects pose a significant challenge in medicine, with current treatments failing to restore cartilage-bone integration, leading to joint degeneration and disabilities. REGENESIS tackles this unmet clinical and market need by developing biomaterial for treating osteochondral microfractures and injuries. Our multidisciplinary approach combines pharmacological stem cell mobilisation and use of homing peptides for precise cell recruitment, cytocompatible photocrosslinking for safety and stability with mechanotransductive biomaterial for tissue-specific repair. REGEniq material offers an optimal solution for knee, ankle and phalange joint injuries while improving outcomes in surgeries like arthroscopy. Advancing REGEniq from TRL3 to TRL5, the project bridges key clinical care and market gaps, ensuring better patient outcomes, lower costs, and fast adoption of regenerative technologies. Clinicians, veterinarians and researchers stand to benefit from REGENESIS’s implementation.
Osteochondral defects pose a significant challenge in medicine, with current treatments failing to restore cartilage-bone integration, leading to joint degeneration and disabilities. REGENESIS tackles this unmet clinical and market need by developing biomaterial for treating osteochondral microfractures and injuries. Our multidisciplinary approach combines pharmacological stem cell mobilisation and use of homing peptides for precise cell recruitment, cytocompatible photocrosslinking for safety and stability with mechanotransductive biomaterial for tissue-specific repair. REGEniq material offers an optimal solution for knee, ankle and phalange joint injuries while improving outcomes in surgeries like arthroscopy. Advancing REGEniq from TRL3 to TRL5, the project bridges key clinical care and market gaps, ensuring better patient outcomes, lower costs, and fast adoption of regenerative technologies. Clinicians, veterinarians and researchers stand to benefit from REGENESIS’s implementation.